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nraveling Questions
urrounding Clopidogrel
esistance and
tent Thrombosis
ne Less Snag*
avid J. Moliterno, MD, FACC,
harles L. Campbell, MD, FACC
exington, Kentucky
atients with symptomatic coronary atherosclerosis tend to
ave recurrent ischemic events despite treatment with
videnced-based therapies, including aspirin and clopi-
ogrel. Recently, it has become appealing to speculate that
ome patients do not receive the anticipated benefit from
ntiplatelet agents because they are nonresponsive or resis-
ant. Several trials have identified patients with relatively
igh platelet activity despite their being treated with aspirin,
lopidogrel, or both. In some of these trials, a failure to
nhibit ex vivo platelet function to a particular extent has
een associated with an increased risk of subsequent isch-
mic events (1,2).
See page 2312
There is a considerable range in the reported prevalence
f antiplatelet resistance, undoubtedly due to variability in
atient populations, comparator groups, treatment regi-
ens, detection methods, and definition cut points. In fact,
recent meta-analysis of 42 studies found the prevalence of
spirin resistance to vary between 0% and 57%, with a mean
f 24% (95% confidence interval 20% to 28%) (3). The most
ecent American College of Cardiology/American Heart
ssociation guidelines for percutaneous coronary interven-
ion (PCI) (4) recommend platelet function testing in
pecific settings and that the clopidogrel maintenance dose
e doubled when antiplatelet resistance is suspected—albeit
ithout randomized study data to support the recommen-
ation. The lack of prospective clinical trial evidence has
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
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ichotomous or whether it exists at all.
In this issue of the Journal, Buonamici et al. (5) provide
bservations from a large reasonably designed study that
uggest PCI patients with inadequate postprocedural plate-
et inhibition are at increased risk for subsequent ischemic
vents. The study enrolled patients receiving drug-eluting
tents for ischemic heart disease presentations ranging from
hronic stable angina to ST-segment elevation myocardial
nfarction. Lesion complexity ranged widely and included
eal-world cases of the left main coronary artery, complex
ifurcation lesions, relatively long lesions, and chronic total
cclusions.
The authors treated all patients with aspirin (325 mg) and
high loading dose (600 mg) of clopidogrel. Platelet
unction testing via light transmittance aggregometry was
erformed 12 to 18 h after clopidogrel loading unless a
lycoprotein (GP) IIb/IIIa inhibitor was given during clo-
idogrel loading. In these situations, light transmittance
ggregometry was performed 6 days later. Patients were
onsidered nonresponsive to clopidogrel if they had residual
latelet aggregation in response to 10 mol/l adenosine
iphosphate 90th percentile of a healthy control group.
he primary end point of the study was definite or probable
tent thrombosis during 6-month follow-up. The secondary
nd point was a composite of cardiac death and definite or
robable stent thrombosis. Definite stent thrombosis was
ngiographically or pathology proven, whereas probable
tent thrombosis was defined as unexplained death or a
yocardial infarction in the territory supplied by the stented
essel.
The study enrolled 804 patients, 13% of whom were
lassified as being nonresponsive to clopidogrel. The non-
esponders appeared to be older and more likely to present
ith severe coronary artery disease, unstable angina, and
iabetes as well as other features previously associated with
tent thrombosis. In particular, they were more likely to
ave multivessel disease, long lesions, chronic occlusions,
nd reduced left ventricular ejection fraction. The respond-
rs were slightly younger and more likely to be current
mokers, present with a thrombotic lesion (acute infarction),
nd receive a GP IIb/IIIa inhibitor.
Overall, stent thrombosis was infrequent, occurring in 25
f 804 patients. Most of these events were probable rather
han definite. When only definite stent thrombosis was
onsidered, the number of events decreased to 11 (1.4%).
he average time to the primary end point was 54 days
range 4 to 180 days). Importantly, clopidogrel nonre-
ponders were more likely than responders to have stent
hrombosis (8.6% vs. 2.3%; p  0.001), but in both groups
atients with multiple risk factors for stent thrombosis, i.e.,
ultivessel disease, complex lesions, and acute presentation,
ere at the highest risk. Nonresponders also were more
ikely to die (8.6% vs. 1.4%; p  0.001) or reach the
econdary composite end point of death or stent thrombosis
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June 19, 2007:2318–9 Editorial Comment10.5% vs. 2.7%; p  0.001). The results of multivariate
nalysis indicated that high residual platelet aggregability
fter dual antiplatelet therapy to be independently associ-
ted with ischemic events following PCI (hazard ratio 3.08,
5% confidence interval 1.32 to 7.16; p  0.009).
There are several outcomes-related issues in this study
orth highlighting. To begin, the primary end point oc-
urred at a low rate (3.1%) and was driven by “probable”
tent thrombosis. Given the severity of coronary disease
mong the clopidogrel nonresponders, it is possible that
ome of these events were unrelated to stent thrombosis.
hat said, the observations from Buonamici et al. (5) are
onsistent with data from a recent presentation of 4 ran-
omized drug-eluting stent trials in which definite stent
hrombosis occurred in 1.0% of patients and possible stent
hrombosis in 5.6% (6).
Next, high residual platelet aggregability was detected in
sizeable proportion of patients (13%), although most in
his subgroup did not experience an adverse event. Again,
hese results are consistent with those from previous studies
7,8). As a diagnostic test for stent thrombosis, the meth-
dology in the current study had low sensitivity (36%) but
oderately high specificity (88%). Unfortunately, if these
esults are used to assign patients to more aggressive
ntiplatelet therapy as recommended by the guidelines (4),
ome patients not destined to experience stent thrombosis
ill need to be overly treated whereas many who will later
evelop stent thrombosis will be missed. In fact, more cases
f stent thrombosis may be missed than treated, and any
rade-off for increased bleeding is unknown. As such, a
andomized trial of more aggressive antiplatelet therapy for
atients considered nonresponders to current dual antiplate-
et therapy is warranted.
There are currently no evidence-based supplemental ther-
pies for patients treated with aspirin and clopidogrel who
ave excess residual platelet activity. Candidate add-ons
nclude periprocedural GP IIb/IIIa inhibitors (7), the ad-
inistration of clopidogrel at a higher dose or frequency (9),
nd cilostazol (10). On the horizon are platelet adenosine
iphosphate-receptor antagonists that are more potent and
aster acting than the current dose of clopidogrel. These
nclude prasugrel, an oral, rapid-acting, irreversible inhibi-
or; AZD6140 an oral, rapid-acting, reversible inhibitor;
nd cangrelor, an intravenous, rapid-acting, and rapidly
eversible agent.
A future antiplatelet resistance-stent thrombosis trial
hould be large and designed to provide insight into the
echanism of the association. To increase trial event rates,
t may be best to focus enrollment on patients at high risk
or stent thrombosis based on clinical and angiographic as
ell as aggregation assessments. Serial analyses of platelet
unction will be helpful mechanistically because variabilityn baseline platelet function affects variability after clopi-
ogrel therapy (11). Additionally, given the fact that me-
hanical revascularization activates platelets (7), the deter-
ination of platelet function in the postprocedure period
nd serially during follow-up may help separate periproce-
ural activation and events from those that are a result of
ngoing vascular disease. The study by Buonamici et al. (5)
urther elevates the association of antiplatelet nonrespon-
iveness and stent thrombosis from a clinical curiosity to a
trong hypothesis worth evaluating in a prospective trial of
elective aggressive antiplatelet therapy.
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